The tachykinin NK1 receptor in the brain: pharmacology and putative functions
about
Biosynthesis and actions of 5-oxoeicosatetraenoic acid (5-oxo-ETE) on feline granulocytesPotential therapeutic targets for neurokinin-1 receptor antagonistsSafety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in catsDrug insight: New antiemetics in the management of chemotherapy-induced nausea and vomitingThe role of substance P in depression: therapeutic implications.Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils.Substance P NK1 receptor in the rat corpus callosum during postnatal development.PET imaging of neurokinin-1 receptors with [(18)F]SPA-RQ in human subjects: assessment of reference tissue models and their test-retest reproducibility.Histological evidence supporting a role for the striatal neurokinin-1 receptor in methamphetamine-induced neurotoxicity in the mouse brain.Human biodistribution and radiation dosimetry of the tachykinin NK1 antagonist radioligand [18F]SPA-RQ: comparison of thin-slice, bisected, and 2-dimensional planar image analysis.Substance P antagonists: novel agents in the treatment of depression.Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI.Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function.Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future.[3H]GR205171 displays similar NK1 receptor binding profile in gerbil and human brain.Aprepitant--a novel NK1-receptor antagonist.An NK1 receptor antagonist microinjected into the periaqueductal gray blocks lateral hypothalamic-induced antinociception in rats.Activation of neurokinin-1 receptors increases the excitability of guinea pig dorsal root ganglion cells.Blocking neurogenic inflammation for the treatment of acute disorders of the central nervous system.Netupitant, a Potent and Highly Selective NK1 Receptor Antagonist, Alleviates Acetic Acid-Induced Bladder Overactivity in Anesthetized Guinea-PigsA structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.The role of substance p in ischaemic brain injury.Pharmacogenetics of chemotherapy-induced nausea and vomiting.N-acetyl-l-tryptophan, but not N-acetyl-d-tryptophan, rescues neuronal cell death in models of amyotrophic lateral sclerosis.Aprepitant for the management of nausea with inpatient IV dihydroergotamine.Trigeminal Medullary Dorsal Horn Neurons Activated by Nasal Stimulation Coexpress AMPA, NMDA, and NK1 Receptors.A remote and highly conserved enhancer supports amygdala specific expression of the gene encoding the anxiogenic neuropeptide substance-P.Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury.Sustained pharmacological blockade of NK1 substance P receptors causes functional desensitization of dorsal raphe 5-HT 1A autoreceptors in mice.Selective blockade of neurokinin (NK)(1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats.Substance P and nitric oxide signaling in cerebral cortex: anatomical evidence for reciprocal signaling between two classes of interneurons.Neurokinin-1 receptor antagonist orvepitant is an effective inhibitor of itch-associated response in a Mongolian gerbil model of scratching behaviour.Neurokinin B induces oedema formation in mouse lung via tachykinin receptor-independent mechanisms.Substance P receptor antagonist and clomipramine prevent stress-induced alterations in cerebral metabolites, cytogenesis in the dentate gyrus and hippocampal volume.Differential effects of aprepitant, a clinically used neurokinin-1 receptor antagonist on the expression of conditioned psychostimulant versus opioid reward.Action of tachykinins in the rat hippocampus: modulation of inhibitory synaptic transmission.Identification of single-nucleotide polymorphisms of the human neurokinin 1 receptor gene and pharmacological characterization of a Y192H variant.The NK1 receptor localizes to the plasma membrane microdomains, and its activation is dependent on lipid raft integrity.AMPA receptors are modulated by tachykinins in rat cerebellum neurons.
P2860
Q21558658-431CC68A-A2BE-4048-B7C2-7E622F1857FCQ28262693-6C5CA0F5-A05D-44B8-BDCD-5416EC0576BDQ28279681-6F5302B6-5681-4454-BEB5-7D83D0359D45Q28280032-416CC335-4713-44F1-86F0-976974DC5E30Q30473429-52AF27E6-229A-462A-9DD8-8947CB14773FQ30479172-E3A43908-A573-4750-AF7E-9D917560AA88Q33810144-FA9DF888-412C-418B-BDDE-D6D1DDE163B4Q33925457-A5A8BDC2-4CCB-47DC-9EF8-DBD8FCBEE333Q33958185-84D0BFA8-DEAC-4E21-892D-5D0C167D8BE5Q34055608-CBF4C482-4BB8-4FFC-B24B-DCBC9A4318ADQ34075030-4CBEA142-B06C-4D43-8E9E-0C50515A5DC2Q34075089-19583488-9FC8-4122-8C2A-721877F80225Q34111110-7791E37A-B936-40FB-9A57-A1B1AC130C90Q35040802-DF730073-4C28-4F70-8B27-D7FE82BE3142Q35100845-AE44EBE3-5726-400A-844E-75ED520E4891Q35594000-BEC3FF52-D3C1-4543-BF3F-0257A694BFBAQ36294073-F7041907-AFE2-4839-9CBC-BA0A579B5FDDQ36296870-8B3775FD-5D59-4245-A67F-8F2FA854919BQ36925594-FFDFEC19-FF29-4CBE-88AF-4B356F8EDB22Q37150382-62B7ABE1-6442-4842-8169-3E7822FA32F5Q37333022-ED90EA95-3146-4396-A2E4-2C02A6EDBC14Q37686937-AD7B9392-9519-4BBC-B6FB-550FF6D4D743Q38222871-D2D28AD1-F889-4788-932F-74250091666FQ38330216-DADEB602-6DAC-412D-AE67-6262C689EC54Q38868878-1448FDB7-79E3-48F6-8327-4C14CEDA4D21Q38954599-BB6D6D34-8B75-4D43-A46B-31F2EB4224EFQ40309623-FFF001E5-1345-4F0A-9683-0D98903F0DBAQ40359293-869C39D4-806E-46EA-A020-0D7E293E3A3DQ42165705-8954908D-65AE-44BB-A94F-8B915F9F0996Q42485195-4797958D-D9D1-4533-8C50-25D28BE8C92CQ43548242-B1C97D74-C18A-45F0-A415-E96FB0D042D5Q43824637-F52E2530-F737-4215-BE13-42506AF34C64Q43908243-AF4D1AB7-C289-4274-8037-3D746C8C1CA2Q44136839-6AE8F3E7-15E1-486A-8278-D5C21BE0DD8DQ44194139-7669B022-74F1-4CDD-AC3F-F6729E4ABCA9Q44342218-6AFC3042-5C98-4BAE-A195-C0BD0ADD871CQ44489191-787BD654-DC00-4A69-90C9-EE8AAE400EECQ45081687-786464E9-826D-495C-88EB-04E421AF1FB9Q45182312-335D9B66-BAA8-47C1-973B-1F1BFACA2809Q46701237-97989EDF-2F3A-4B27-A5F1-AFBD85D24EA6
P2860
The tachykinin NK1 receptor in the brain: pharmacology and putative functions
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The tachykinin NK1 receptor in the brain: pharmacology and putative functions
@ast
The tachykinin NK1 receptor in the brain: pharmacology and putative functions
@en
The tachykinin NK1 receptor in the brain: pharmacology and putative functions
@nl
type
label
The tachykinin NK1 receptor in the brain: pharmacology and putative functions
@ast
The tachykinin NK1 receptor in the brain: pharmacology and putative functions
@en
The tachykinin NK1 receptor in the brain: pharmacology and putative functions
@nl
prefLabel
The tachykinin NK1 receptor in the brain: pharmacology and putative functions
@ast
The tachykinin NK1 receptor in the brain: pharmacology and putative functions
@en
The tachykinin NK1 receptor in the brain: pharmacology and putative functions
@nl
P921
P3181
P1476
The tachykinin NK1 receptor in the brain: pharmacology and putative functions
@en
P2093
P3181
P356
10.1016/S0014-2999(99)00259-9
P407
P577
1999-06-30T00:00:00Z